Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Common Equity (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Common Equity for 7 consecutive years, with $38.2 million as the latest value for Q3 2024.

  • On a quarterly basis, Common Equity fell 12.33% to $38.2 million in Q3 2024 year-over-year; TTM through Sep 2024 was $38.2 million, a 12.33% decrease, with the full-year FY2023 number at $36.4 million, down 45.28% from a year prior.
  • Common Equity was $38.2 million for Q3 2024 at Actinium Pharmaceuticals, down from $43.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $80.5 million in Q2 2021 to a low of $36.4 million in Q4 2023.
  • A 4-year average of $60.4 million and a median of $66.5 million in 2022 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: dropped 2.68% in 2022, then crashed 45.28% in 2023.
  • Actinium Pharmaceuticals' Common Equity stood at $73.5 million in 2021, then fell by 9.61% to $66.5 million in 2022, then plummeted by 45.28% to $36.4 million in 2023, then rose by 5.03% to $38.2 million in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Common Equity are $38.2 million (Q3 2024), $43.8 million (Q2 2024), and $43.9 million (Q1 2024).